Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease

NCT00353756 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: C326, IL-6 Inhibitory Avimer protein

Sponsor

Avidia